{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"26.5","upperLimit":"46.7","value":"36.2"},{"groupId":"OG001","lowerLimit":"6.6","upperLimit":"21.7","value":"12.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"86"}],"units":"Participants"}],"title":"Participants with baseline PD-L1 expression ≥ 5%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.3","upperLimit":"17.4","value":"10.9"},{"groupId":"OG001","lowerLimit":"9.1","upperLimit":"21.5","value":"14.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"138"}],"units":"Participants"}],"title":"Participants with baseline PD-L1 expression < 5%"}],"denoms":[{"counts":[{"groupId":"OG000","value":"231"},{"groupId":"OG001","value":"224"}],"units":"Participants"}],"description":"ORR was defined as the percentage of all randomized participants whose Best Overall Response (BOR) was a confirmed Complete Response (CR) or Partial Response (PR). CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.; PR = At least a 30% decrease in the sum of diameters of target lesions, taking, as reference, the baseline sum diameters. CR+PR, confidence interval based on the Clopper and Pearson method. ORR was reported for all randomized participants grouped by their baseline PD-L1 expression level. PD-L1 expression in participants was defined as the percent of disease tumor cells demonstrating plasma membrane PD-L1 staining of any intensity using an immunohistochemistry (IHC) assay.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.","id":"OG000","title":"Nivolumab"},{"description":"Docetaxel 75mg/m\\^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.","id":"OG001","title":"Docetaxel"}],"paramType":"NUMBER","populationDescription":"All randomized participants who had a tumor biopsy assessed for PD-L1 expression","reportingStatus":"POSTED","timeFrame":"From randomization to date of objectively documented progression (up to approximately 110 months)","title":"Objective Response Rate (ORR) by PD-L1 Expression at Baseline","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}